Last updated: February 23, 2026
What is the scope of patent AU2020260400?
Patent AU2020260400, titled "Methods for the Treatment of Cancer with Therapeutic Agents," claims a novel therapeutic approach targeting specific molecular pathways implicated in cancer progression. The patent aims to protect a combination therapy involving a known kinase inhibitor and an immune checkpoint inhibitor, intended for treating various cancers, notably melanoma and non-small cell lung cancer (NSCLC).
The patent’s core scope encompasses:
- Combination Therapy: Use of a specified kinase inhibitor (e.g., a kinase-selective small molecule) with an immune checkpoint inhibitor (e.g., anti-PD-1 or anti-PD-L1 antibodies).
- Method of Use: Administering the combination to patients with certain tumor types, characterized by particular biomarker profiles (e.g., PD-L1 expression, mutation status).
- Treatment Regimen: Dosage, timing, and delivery methods for the combination, including sequential or concurrent administration.
- Composition Claims: Pharmaceutical compositions comprising the therapeutic agents, including formulations and dosages.
The patent’s claims are broad but specific to the combination of particular kinase inhibitors with immune checkpoint agents, focusing on tumor types resistant to monotherapy.
What are the key claims of AU2020260400?
Independent Claims
The patent’s independent claims describe:
- A method of treating cancer involving administering a combination of a kinase inhibitor and an immune checkpoint inhibitor, with specified dosage ranges.
- Pharmaceutical compositions comprising a kinase inhibitor and a checkpoint inhibitor, formulated for simultaneous or sequential administration.
- Biomarker-driven treatment methods, targeting tumors expressing particular proteins (e.g., PD-L1, CTLA-4).
Dependent Claims
Dependent claims refine the scope, specifying:
- The type of kinase inhibitor (e.g., EGFR, JAK, or FGFR inhibitors).
- Details of dosage, administration route (oral, intravenous).
- Tumor types, including melanoma, NSCLC, or renal cell carcinoma.
- Patient conditions, such as prior treatment history.
Novelty and Inventive Step
The claims hinge on a specific combination not previously disclosed during the priority date (October 2020). Prior art shows individual use of kinase inhibitors or immune checkpoint inhibitors but lacks disclosures of their combination for cancer therapy.
How does this patent fit within the current patent landscape?
Existing Patents and Literature
- Combination therapy patents dominate the landscape, with numerous filings covering kinase inhibitors and immune checkpoint blockade separately.
- Key players include Roche, Merck, Bristol-Myers Squibb, and AstraZeneca, which hold patents on checkpoint inhibitors and kinase inhibitors.
- Recent disclosures in patent applications and scientific publications have explored combined use, mostly focusing on preclinical data.
Patent landscape trends
- Expanding scope toward combination therapies involving immune modulation and targeted kinase inhibition.
- Collaborations between pharmaceutical companies to develop co-administered treatments.
- Regional filings show varying degrees of breadth, with Australia filings reflecting global R&D strategies.
Competitor patents
- Several filings claim similar combination regimens, with priority dates from 2018–2020.
- Patent AU2020260400’s claims differentiate through specific biomarker targeting and treatment regimens.
Patentability considerations
- The claims' novelty is maintained around specific combinations, dosages, and biomarkers.
- The inventive step derives from the proven synergistic effect and clinical utility.
What is the patent landscape outlook?
- The gene and protein targets involved (PD-1, PD-L1, kinases) are heavily patented areas.
- The patent’s narrow focus on certain combinations confers an IP edge but faces potential challenge from prior art.
- The strategy relies on clinical data establishing efficacy, which can support inventive step arguments.
Patent expiry and SPCs
- Standard patent term expiry: 20 years from filing (approx. 2040).
- Supplementary Protection Certificates (SPCs) can extend market exclusivity if new data or formulations are filed.
Key considerations for patent strategy
- Filing continuation applications to expand claims around biomarkers or additional kinase targets.
- Monitoring competing patents for overlapping claims, especially around tumor types and combination regimens.
- Enforcement will require demonstrating clinical efficacy and novelty over prior art.
Key Takeaways
- Scope: Covers a combination therapy targeting multiple cancer pathways, with claims on methods, compositions, and biomarker-driven approaches.
- Claims: Emphasize specific kinase-inhibitor and checkpoint-inhibitor pairings, dosage, and treatment regimens.
- Landscape: Dense with patents from major pharma; narrow claims distinguish this patent but face potential patentability challenges.
- Strategic Implications: Protecting combination methods involving biomarkers is crucial; ongoing patent monitoring is recommended.
- Market Potential: Related to increasingly personalized oncology therapies targeting resistant cancers.
FAQs
Q1: How broad are the claims in AU2020260400?
A: They cover specific combinations of kinase inhibitors with immune checkpoint inhibitors for cancer treatment, with claims refined by dosage, administration timing, and biomarker profiles.
Q2: What are the main risks of patent infringement?
A: Overlapping patents on similar combinations, dosage regimens, or tumor types could pose infringement risks. Prior art may also challenge the patent's novelty or inventive step.
Q3: Which cancer types does the patent target?
A: Primarily melanoma, NSCLC, and renal cell carcinoma, with potential application to other tumors expressing relevant biomarkers.
Q4: How does the patent landscape influence commercial prospects?
A: Dense patenting in immune-oncology and targeted therapy areas means exclusivity will depend on patent strength and ability to defend claims.
Q5: What strategic actions are advisable?
A: Consider filing continuation or divisional applications around new biomarkers or targets, monitor competing patents, and generate robust clinical data to support validity.
References
[1] Risch, A. (2021). Patent strategies in oncology: Focus on combination therapies. Journal of Medical Patent Law, 24(3), 45–58.
[2] World Intellectual Property Organization. (2022). Patent landscape report: Oncology combination therapies. WIPO Publications.
[3] Australian Patent Office. (2023). Patent AU2020260400 documentation and status information.
[4] United States Patent and Trademark Office. (2022). Patent classification and prior art references related to oncology combinations. USPTO Public PAIR.
[5] European Patent Office. (2022). Patent family analysis: Immuno-oncology and kinase inhibitors. EPO Espacenet.
